Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [18F]Fluorodeoxyglucose positron emission tomography use, honed on adrenocortical carcinoma

doi:10.5306/wjco.v16.i6.106511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=0

Jun 24, 2025 (publication date) through Jun 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Jun 24, 2025; 16(6): 106511
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.106511

Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [¹⁸F]Fluorodeoxyglucose positron emission tomography use, honed on adrenocortical carcinoma

Ioannis Ilias, Georgios Meristoudis

Ioannis Ilias, Department of Endocrinology, Hippocration General Hospital, Athens GR-11527, Greece

Georgios Meristoudis, Department of Nuclear Medicine, Hippokration General Hospital, Thessaloniki 54643, Greece

Author contributions: Ilias I and Meristoudis G conceived, performed the literature search and wrote this paper; Both authors agree to this paper's submission.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ioannis Ilias, MD, PhD, Director, Department of Endocrinology, Hippocration General Hospital, 63, Evrou Street, Athens GR-11527, Greece. iiliasmd@yahoo.com

Received: February 28, 2025
Revised: March 20, 2025
Accepted: April 25, 2025
Published online: June 24, 2025
Processing time: 112 Days and 16.3 Hours

Core Tip

Core Tip: [¹⁸F]Fluorodeoxyglucose positron emission tomography (FDG PET) diagnostic performance for adrenal incidentalomas (AdIn) was evaluated based on their size as measured on computed tomography (CT) and their unenhanced density in Hounsfield units (HU), using a 20 HU cutoff to assess adrenocortical carcinoma (ACC) risk. The likelihood ratios for positive/negative tests do not meet the usual thresholds, respectively, indicating strong but not definitive diagnostic accuracy. FDG PET should be combined with CT or magnetic resonance imaging for optimal assessment of AdIns.